| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8518987 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Feb, 2024
(4 months from now) | |
| US7390791 | JANSSEN PRODS | Prodrugs of phosphonate nucleotide analogues |
Apr, 2025
(1 year, 6 months from now) | |
| US7700645 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Dec, 2026
(3 years from now) | |
| US8148374 | JANSSEN PRODS | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(5 years from now) | |
| US9296769 | JANSSEN PRODS | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| US8754065 | JANSSEN PRODS | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7803788 | JANSSEN PRODS | Prodrugs of phosphonate nucoleotide analogues |
Feb, 2022
(1 year, 7 months ago) | |
| US10039718 | JANSSEN PRODS | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Oct, 2032
(9 years from now) | |
| US10786518 | JANSSEN PRODS | Compositions and methods of treating HIV |
Jul, 2038
(14 years from now) | |
Symtuza is owned by Janssen Prods.
Symtuza contains Cobicistat; Darunavir; Emtricitabine; Tenofovir Alafenamide Fumarate.
Symtuza has a total of 9 drug patents out of which 1 drug patent has expired.
Expired drug patents of Symtuza are:
- US7803788
Symtuza was authorised for market use on 17 July, 2018.
Symtuza is available in tablet;oral dosage forms.
Symtuza can be used as tx of hiv-1 infection using a composition containing a pk enhancer that inhibits cytochrome p450 monooxygenates in adults who have no prior antiretroviral tx history or are virologically suppressed on a stable antiretroviral regimen for at least 6 months; treatment of hiv-1 infection using a composition containing a pk enhancer that inhibits cy p450 monoxygenase in adults and pediatric patients weighing at least 40kg who have no prior arv treatment history; treatment of hiv-1 infection using a composition containing a pk enhancer that inhibits cy p450 monoxygenase in adults and pediatric patients weighing at least 40kg who are virologically suppressed on a stable arv regimen for at least 6 months; tx of hiv1 infection using a composition containing a pk enhancer that inhibits cy p450 monoxygenase in adults & pediatric patients at least 40kg having no prior arv tx history or are virologically suppressed on a stable arv regimen for at least 6 mo; treatment of hiv-1 infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase in adults who have no prior antiretroviral treatment history; treatment of hiv-1 infection using a composition containing a pharmacokinetic enhancer that inibits cytochrome p450 monooxygenase in adults who are virologically suppressed on a stable antiretroviral regimen for at least 6 months, treatment of hiv-1 infection in adult or pediatric patients (>=40 kg) with <50 copies/ml hiv-1 rna after >= 6 months on prior antiretroviral regimen and no known darunavir or tenofovir resistance-associated substitutions, treatment of hiv-1 infection in adults who have no prior antiretroviral treatment history or are virologically suppressed on a stable antiretroviral regimen for at least 6 months; treatment of hiv-1 infection in adults and pediatric patients weighing at least 40 kg who have no prior antiretroviral treatment history or are virologically suppressed on a stable antiretroviral regimen for at least 6 months.
The generics of Symtuza are possible to be released after 19 July, 2038.
Market Authorisation Date: 17 July, 2018
Treatment: Treatment of hiv-1 infection in adults who have no prior antiretroviral treatment history or are virologically suppressed on a stable antiretroviral regimen for at least 6 months; Treatment of hiv-1 i...
Dosage: TABLET;ORAL
SYMTUZA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic